- Home
- JRVR vs TARA Comparison
JRVR vs TARA Comparison
Compare JRVR & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRVR | TARA |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.2M | 269.8M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | JRVR | TARA |
|---|---|---|
| Price | $3.92 | $4.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $7.33 | ★ $24.40 |
| AVG Volume (30 Days) | 585.2K | ★ 753.3K |
| Earning Date | 05-04-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 125.82 | 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $687,614,000.00 | $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.76 | $2.77 |
| 52 Week High | $7.20 | $7.82 |
Technical Indicators
Market Signals| Indicator | JRVR | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 24.71 | 40.41 |
| Support Level | $3.76 | $4.21 |
| Resistance Level | $4.42 | $5.53 |
| Average True Range (ATR) | 0.20 | 0.31 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 20.45 | 28.22 |
Price Performance
Historical ComparisonAbout JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.